You are leaving the Blue Earth Therapeutics website. By clicking this link, you will be taken to a website that is independent from Blue Earth Therapeutics. The site you are linking to is not controlled or endorsed by Blue Earth Therapeutics and Blue Earth Therapeutics is not responsible for the content provided on that site.

ACCEPT
CANCEL

This page is intended for Healthcare Professionals only. Are you a Healthcare Professional?

Yes No

PIPELINE

Blue Earth Therapeutics is developing targeted radiopharmaceuticals to transform the clinical management of patients with cancer.

The company has acquired exclusive worldwide rights to radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) targeted technology for therapeutic use and has a research programme initially focused on prostate cancer. The rhPSMA molecule is being investigated in two programmes; one using the beta emitting radioisotope lutetium-177 (177Lu), and one using the alpha emitter actinium-225 (225Ac).

OUR PIPELINE

Blue Earth Therapeutics is investigating the use of the rhPSMA molecule for prostate cancer therapy with the addition of an alpha or beta emitting radioisotope.

Product / Candidate
Disease / Therapeutic Area
Application
Disease / Therapeutic Area
Application
Status
Preclinical
Phase 1
Phase 2
Phase 3
177Lu-rhPSMA-10.1
Prostate Cancer
Radiopharmaceutical Therapy
Prostate Cancer
Radiopharmaceutical Therapy
Preclinical
Phase 1
Phase 2
Phase 3
225Ac-rhPSMA-10.1
Prostate Cancer
Radiopharmaceutical Therapy
Prostate Cancer
Radiopharmaceutical Therapy
Preclinical
Phase 1
Phase 2
Phase 3

177Lu-rhPSMA-10.1 is currently being studied to evaluate its safety profile, tolerability, radiation dosimetry and anti-tumour activity in men with metastatic castrate-resistant prostate cancer (NCT05413850).

https://www.clinicaltrials.gov/ct2/show/NCT05413850?term=NCT05413850

UKBET-rh-2500048 / October 2025